Discovery of novel inhibitors of human 11β-hydroxysteroid dehydrogenase type 1

Molecular and Cellular Endocrinology

Volumn 301, Issue 1-2, 2009, Pages 169-173

  Su, Xiangdong ^a   Vicker, Nigel ^a   Trusselle, Melanie ^a   Halem, Heather ^b   Culler, Michael D ^b   Potter, Barry V L ^a  

^a University of Bath   (United Kingdom)

^b Biomeasure Inc   (United States)

Author keywords

11 HSD1; Adamantane; Diabetes; Hydroxysteroid dehydrogenase; Inhibitors; Obesity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 2 (ADAMANTAN 1 YL) N METHYL N (THIOPHEN 3 YLMETHYL)ACETAMIDE; 2 ADAMANTAN 1 YL N METHYL N THIOPHEN 2 YLMETHYL ACETAMIDE; 5 (ADAMANTAN 1 YLCARBONYL) 4H,5H,6H,7H THIENO[3,2 C]PYRIDINE; N (4 CHLORO 2 METHYL 1,3 BENZOTHIAZOL 5 YL)ADAMANTANE 1 CARBOXAMIDE; N (FURAN 2 YLMETHYL) N METHYLADAMANTANE 1 CARBOXAMIDE; N (THIOPHEN 2 YLMETHYL)ADAMANTANE 1 CARBOXAMIDE; N [(1 METHYL 1H PYRROL 2 YL)METHYL]ADAMANTANE 1 CARBOXAMIDE; N [2 (THIOPHEN 2 YL)ETHYL]ADAMANTANE 1 CARBOXAMIDE; N METHYL N (THIOPHEN 2 YLMETHYL)ADAMANTANE 1 CARBOXAMIDE; N METHYL N (THIOPHEN 3 YLMETHYL)ADAMANTANE 1 CARBOXAMIDE; N METHYL N [(1 METHYL 1H PYRROL 2 YL)METHYL]ADAMANTANE 1 CARBOXAMIDE; N METHYL N [2 (THIOPHEN 2 YL)ETHYL]ADAMANTANE 1 CARBOXAMIDE; OXIDOREDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG INHIBITION; DRUG SYNTHESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; CELL LINE; CORTISONE; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; HYDROCORTISONE; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; NADP;

EID: 60249092811     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.08.006     Document Type: Article

References (13)

1. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The protein data bank. Nucleic Acids Res. 28 (2000) 235-242
2. Hawkins M., Hunter D., Kishore P., Schwartz S., Hompesch M., Hollis G., Levy R., Williams B., and Huber R. INCB013739, a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus. Proceedings of the New and Novel Treatments for Diabetic Complications, the American Diabetes Association 68th Scientific Sessions. June 6-10, San Francisco, CA, 344-OR (2008)
3. Hermanowski-Vosatka A., Balkovec J.M., Cheng K., Chen H.Y., Hernandez M., Koo G.C., Le Grand C.B., Li Z., Metzger J.M., Mundt S.S., Noonan H., Nunes C.N., Olson S.H., Pikounis B., Ren N., Robertson N., Schaeffer J.M., Shah K., Springer M.S., Strack A.M., Strowski M., Wu K., Wu T., Xiao J., Zhang B.B., Wright S.D., and Thieringer R. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 202 (2005) 517-527
4. Hosfield D.J., Wu Y., Skene E.J., Hilgers M., Jennings A., Snell G.P., and Aertgeerts K. Conformational flexibility in crystal structures of human 11β-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation. J. Biol. Chem. 280 (2005) 4639-4648
5. Hughes K.A., Webster S.P., and Walker B.R. 11-Beta-hydroxysteroid dehydrogenase type 1 (11-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin. Investig. Drugs 17 (2008) 481-496
6. Oppermann U. Type 1 11β-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?. Endocr. Metab. Immune Disord. Drug Targets 6 (2006) 259-269
7. Schweizer R.A.S., Atanasov A.G., Frey B.M., and Odermatt A. A rapid screening assay for inhibitors of 11β-hydroxysteroid dehydrogenases (11β-HSD): flavanone selectively inhibits 11β-HSD1 reductase activity. Mol. Cell. Endocrinol. 212 (2003) 41-49
8. Su X., Vicker N., Ganeshapillai D., Smith A., Purohit A., Reed M.J., and Potter B.V.L. Benzothiazole derivatives as novel inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrinol. 248 (2006) 214-217
9. Su X., Vicker N., and Potter B.V.L. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Prog. Med. Chem. 46 (2008) 30-118
10. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., Hewison M., and Stewart P.M. 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25 (2004) 831-866
11. Vicker, N., Su, X., Pradaux, F., Reed, M.J., Potter, B.V.L., 2006. Adamantane carboxylic acid derivatives as 11β-hydroxysteroid dehydrogenase inhibitors and their preparation, pharmaceutical compositions and used for treatment of various diseases. WO2006100502.
12. Vicker N., Su X., Ganeshapillai D., Smith A., Purohit A., Reed M.J., and Potter B.V.L. Novel non-steroidal inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. J. Steroid Biochem. Mol. Biol. 104 (2007) 123-129
13. Walker B.R., Connacher A.A., Lindsay M., Webb D.J., and Edwards C.R.W. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrinol. Metab. 80 (1995) 3155-3159